Replies to post #89897 on Biotech Values

[DewDiligence]

AZN is terminating drug-discovery work in the following fields: schizophrenia, bipolar disease, depression, anxiety, acid reflux, thrombosis, ovarian and bladder cancers, systemic scleroderma, and hepatitis C:

http://www.reuters.com/article/idCNLDE62019Q20100302

This decision does not affect drugs already in development.